ASO Author Reflections: Early Recurrence After Esophageal Cancer Resection Cannot be Predicted Preoperatively: A Call for More Reliable Biomarkers.
作者信息
Rompen Ingmar F, Billeter Adrian T, Crnovrsanin Nerma, Sisic Leila, Neuschütz Kerstin J, Musa Julian, Bolli Martin, Fourie Lana, Kraljevic Marko, Al-Saeedi Mohammed, Nienhüser Henrik, Müller-Stich Beat P
机构信息
Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Department of Surgery, Clarunis-University Digestive Health Care Center, St. Clara Hospital and University Hospital Basel, Basel, Switzerland.
出版信息
Ann Surg Oncol. 2025 Mar;32(3):1679-1680. doi: 10.1245/s10434-024-16466-4. Epub 2024 Nov 18.
Abstract
摘要
相似文献
1
ASO Author Reflections: Early Recurrence After Esophageal Cancer Resection Cannot be Predicted Preoperatively: A Call for More Reliable Biomarkers.ASO作者反思：食管癌切除术后早期复发无法术前预测：呼吁更可靠的生物标志物
Ann Surg Oncol. 2025 Mar;32(3):1679-1680. doi: 10.1245/s10434-024-16466-4. Epub 2024 Nov 18.
2
ASO Author Reflections: Effectiveness of Resection of Oligometastases from Esophageal Cancer.ASO作者反思：食管癌寡转移灶切除术的有效性
Ann Surg Oncol. 2020 Mar;27(3):660-661. doi: 10.1245/s10434-019-08179-w. Epub 2020 Jan 6.
3
ASO Author Reflections: Surveillance for Early Detection of Tumor Recurrence after Esophagectomy in Patients with Esophageal Cancer.美国外科医师学会（ASO）作者反思：食管癌患者食管切除术后肿瘤复发早期检测的监测
Ann Surg Oncol. 2023 Apr;30(4):2198-2199. doi: 10.1245/s10434-022-12740-5. Epub 2022 Dec 6.
4
ASO Author Reflections: Is Esophagectomy Necessary after Noncurative Endoscopic Resection for Early Esophageal Squamous Cell Carcinoma?ASO作者反思：早期食管鳞状细胞癌非根治性内镜切除术后是否需要进行食管切除术？
Ann Surg Oncol. 2021 Nov;28(12):7160-7161. doi: 10.1245/s10434-021-10473-5. Epub 2021 Jul 15.
5
ASO Author Reflections: Predicting Very Early Recurrence After Resection of Gastric Cancer.ASO作者反思：预测胃癌切除术后的极早期复发
Ann Surg Oncol. 2022 Dec;29(13):8662-8663. doi: 10.1245/s10434-022-12471-7. Epub 2022 Aug 23.
6
ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses.ASO作者反思：使用微小RNA生物标志物在手术前预测食管腺癌对放化疗的反应，有望通过根据预测反应调整治疗方案来改善治疗结果。
Ann Surg Oncol. 2018 Dec;25(Suppl 3):755-756. doi: 10.1245/s10434-018-6958-8. Epub 2018 Oct 25.
7
ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma.ASO作者反思：预测食管腺癌三联疗法后的早期复发
Ann Surg Oncol. 2018 Dec;25(Suppl 3):964-965. doi: 10.1245/s10434-018-7016-2. Epub 2018 Nov 15.
8
ASO Author Reflections: Recurrence After Pathological Complete Response in Esophageal Cancer: Analysis of Risk Factors for this Unexpected Event.ASO作者反思：食管癌病理完全缓解后的复发：对这一意外事件的危险因素分析
Ann Surg Oncol. 2021 Jun;28(6):3044-3045. doi: 10.1245/s10434-020-09352-2. Epub 2020 Nov 11.
9
ASO Author Reflections: The Optimal Circumferential Resection Margin in Pathological T3 Esophageal Cancer.ASO作者反思：病理T3期食管癌的最佳环周切缘
Ann Surg Oncol. 2022 Mar 5. doi: 10.1245/s10434-022-11492-6.
10
ASO Author Reflections: Achieving Adequate Lymphadenectomy in Esophageal Cancer Resection.ASO作者反思：食管癌切除术中实现充分的淋巴结清扫
Ann Surg Oncol. 2020 Oct;27(11):4457-4458. doi: 10.1245/s10434-020-08588-2. Epub 2020 May 14.
引用本文的文献
1
A Hard Pill to Swallow: The Problem of Recurrence in Esophageal and Gastroesophageal Junction Carcinomas.难以下咽的苦果：食管及食管胃交界癌的复发问题
Ann Surg Oncol. 2025 Mar;32(3):1401-1402. doi: 10.1245/s10434-024-16589-8. Epub 2024 Nov 23.
本文引用的文献
1
Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An International Multicenter Study.导管内乳头状黏液性肿瘤衍生胰腺癌的最佳治疗策略：早期复发的定义与预测——一项国际多中心研究
Ann Surg Oncol. 2025 Mar;32(3):1879-1886. doi: 10.1245/s10434-024-16649-z. Epub 2024 Dec 12.
2
Definition and Predictors of Early Recurrence in Neoadjuvantly Treated Esophageal and Gastroesophageal Adenocarcinoma: a Dual-Center Retrospective Cohort Study.新辅助治疗的食管和食管胃腺癌早期复发的定义及预测因素：一项双中心回顾性队列研究
Ann Surg Oncol. 2025 Mar;32(3):1617-1627. doi: 10.1245/s10434-024-16403-5. Epub 2024 Nov 5.
3
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.胃和胃食管结合部腺癌的新辅助阿替利珠单抗联合化疗：Ⅱ期 PANDA 试验。
Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8.
4
Age-dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction: a multicenter retrospective observational study of young versus old patients.年龄依赖性新辅助治疗在食管胃交界腺癌中的获益：一项比较年轻患者与老年患者的多中心回顾性观察性研究。
Int J Surg. 2023 Dec 1;109(12):3804-3814. doi: 10.1097/JS9.0000000000000713.
5
Pattern and time point of relapse in locally advanced esophagogastric adenocarcinoma after multimodal treatment: implications for a useful structured follow-up.局部晚期食管胃腺癌多模式治疗后复发的模式和时间点：对有用的结构化随访的意义。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14785-14796. doi: 10.1007/s00432-023-05254-4. Epub 2023 Aug 17.
6
CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison.食管癌和食管胃交界腺癌中CROSS方案与FLOT方案的比较：一项倾向评分匹配比较
Ann Surg. 2022 Nov 1;276(5):792-798. doi: 10.1097/SLA.0000000000005617. Epub 2022 Jul 25.
Zotero 插件